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a b s t r a c t
In our in vitro model for HPV16-mediated transformation, HPV16-immortalized human keratinocytes
(HKc/HPV16) give rise to differentiation resistant, premalignant cells (HKc/DR). HKc/DR, but not HKc/
HPV16, are resistant to growth inhibition by transforming growth factor beta (TGF-β), due to a partial
loss of TGF-β receptor type I. We show that TGF-β activates a Smad-responsive reporter construct in HKc/
DR to about 50% of the maximum levels of activation observed in HKc/HPV16. To investigate the
functional signiﬁcance of residual TGF-β signaling in HKc/DR, we compared gene expression proﬁles
elicited by TGF-β treatment of HKc/HPV16 and HKc/DR on Agilent 44k human whole genome
microarrays. TGF-β altered the expression of cell cycle and MAP kinase pathway genes in HKc/HPV16,
but not in HKc/DR. However, epithelial–mesenchymal transition (EMT) responses to TGF-β were
comparable in HKc/HPV16 and HKc/DR, indicating that the signaling pathways through which TGF-β
elicits growth inhibition diverge from those that induce EMT in HPV16-transformed cells.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Cervical cancer ranks second as a leading cause of cancer-
related deaths among women worldwide (Vaccarella et al., 2013).
High-risk human papillomaviruses (HR-HPV), the etiologic agent
of cervical cancer (zur Hausen, 2000), immortalize human kerati-
nocytes (HKc) in culture (Pirisi et al., 1987, 1988; Kaur and
McDougall, 1988). Both in vitro and in vivo, HPV-mediated trans-
formation is elicited by the HR-HPV E6 and E7 oncoproteins, which
bind to and functionally inactivate tumor suppressor proteins p53
and pRb, respectively (Scheffner et al., 1990; Munger et al., 1989).
Infection with HR-HPV is necessary but not sufﬁcient to produce
cervical cancer, suggesting that additional factors contribute to
cervical cancer progression (zur Hausen, 2000). To study the
molecular and cellular changes accompanying HPV-mediated
transformation, our laboratory has established an in vitro model
using HPV16 DNA and normal foreskin HKc. HKc immortalized by
transfection with HPV16 DNA (HKc/HPV16) progress towards
malignancy via a series of phenotypically well-deﬁned and repro-
ducible steps, including growth factor independent (HKc/GFI) and
differentiation resistant (HKc/DR) stages (Pirisi et al., 1988). Inter-
estingly, HKc/DR but not HKc/HPV16 or HKc/GFI undergo
malignant conversion upon transfection with v-ras or herpes
simplex virus 2 (HSV2) DNA (DiPaolo et al., 1990, 1989).
Transforming growth factor-beta (TGF-β) is a multifunctional
cytokine that regulates numerous biological processes, including
wound healing, embryogenesis and immune cell functions in a
variety of conditions including ﬁbrotic diseases and cancer
(Chuang et al., 2013; Massague, 2008). In cancer, the biological
responses elicted by TGF-β depend on the cell type and surround-
ing microenvironment. For example, TGF-β inhibits cell prolifera-
tion in normal tissue and at early stages of carcinogenesis.
However, during progression, tumor cells become partly or com-
pletely resistant to growth inhibition by TGF-β, which instead
stimulates tumor cell growth and cell survival (see Wendt et al.,
2012 for a recent review). Accordingly, we have previously shown
that while HKc/HPV16 are sensitive to the growth inhibitory
effects of TGF-β, HKc/DR are resistant (Creek et al., 1994; Mi
et al., 2000; Hypes et al., 2009).
TGF-β elicits intracellular signals through cell surface receptors
of the serine/threonine kinase family and via the Smad proteins,
downstream of the receptors, although non-Smad pathways of
TGF-β signaling also exist (Massague et al., 2000; Seoane, 2006;
Ten Dijke et al., 2002; Zhang, 2009). HKc/DR's complete resistance
to growth inhibition by TGF-β is associated with a partial loss of
TGF-β receptor type I (TGFBRI) expression (Mi et al., 2000).
However, TGF-β signaling is not completely lost in HKc/DR, as
TGF-β treatment of these cells partially represses E7 expression
(Borger et al., 2000) and decreases Ski protein levels (Baldwin
et al., 2004; Chen et al., 2013). Importantly, re-expression of
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exogenous TGFBRI in HKc/DR fully restores sensitivity to growth
inhibition by TGF-β (Mi et al., 2000).
The primary goal of this study was to explore the functional
signiﬁcance of the TGF-β signaling still present in HKc/DR, and
the possible differences in gene expression responses elicited by
TGF-β in HKc/HPV16 and HKc/DR. Hence, we further explored
Smad signaling in HKc/DR, and then compared the gene expres-
sion proﬁles of HKc/HPV16 and HKc/DR treated with or without
TGF-β1 on Agilent 444k human oligonucleotide microarrays.
We found that a 50% reduction in Smad signaling in HKc/DR is
associated with a complete loss of gene expression responses to
TGF-β related to growth inhibition. In addition, and most inter-
estingly, TGF-β elicits the same EMT and cell motility gene
expression proﬁles in both HKc/HPV16 and HKc/DR. Therefore, in
this model of HPV16-mediated transformation, the functional
activities of TGF-β that predominate when this cytokine's role
“switches” from tumor suppressor to tumor promoter, during
cancer progression, are present from early stages of transforma-
tion. However, in HKc/HPV16 the growth inhibitory effects of TGF-
β predominate, while in HKc/DR TGF-β elicits only EMT and cell
motility responses.
Results
TGF-β activation of a Smad-responsive reporter construct
in HKc/HPV16 and HKc/DR
To compare the extent of Smad-dependent signaling in HKc/
HPV16 and HKc/DR, we performed dose–response curves of TGF-
β1 induction of p6SBE-Luc activity in four independently-derived
HKc/HPV16 lines and their corresponding HKc/DR lines. We
determined that p6SBE-Luc activity is induced maximally in both
HKc/HPV16 and HKc/DR by about 10 pM TGF-β, with no further
induction of the reporter by TGF-β1 concentrations as high as 75
pM (Fig. 1). However, while ΤGF-β1 induced p6SBE-Luc activity by
8.7 to 12.2-fold in the HKc/HPV16 lines, the reporter was only
activated by 3.2 to 5.9-fold in the HKc/DR lines (Fig. 1). As
expected, the p6SME control plasmid did not show induction by
TGF-β1 at any concentration in either HKc/HPV16 or HKc/DR (data
not shown).
Identiﬁcation of differentially regulated genes in HKc/HPV16
and HKc/DR treated with and without TGF-β
To investigate the functional signiﬁcance of the TGF-β signaling
remaining in HKc/DR, we compared the gene expression proﬁles of
HKc/HPV16 and HKc/DR treated with and without 40 pM TGF-β1
for 48 h. A schematic representation of the microarray study
design is presented in Fig. 2A. To identify genes that exhibited
statistically signiﬁcant expression changes in TGF-β-treated cells
versus controls, we performed a pairwise t test analysis of the
microarray data at po0.05, with a cut-off of two-fold (up or
down). All four HKc/HPV16 and HKc/DR dye-swap microarray
pairs were selected for analysis, thus n¼8 for all culture conditions
and cell lines.
The scatter plots in Fig. 2B show a graphical view of the
expression levels of all genes on the microarrays, from all four
HKc/HPV16 lines and all four HKc/DR lines. Red corresponds to
spots with increased signal (TGF-β treated vs control) on the
microarray; spots with decreased signal are shown in green, and
the gray area represents spots that do not meet the two-fold
change cutoff criteria in either direction. For HKc/HPV16 treated
with TGF-β1, the scatter plot shows a balanced distribution of up-
regulated and down-regulated genes (Fig. 2B, HKc/HPV16). How-
ever, many more spots had an increased signal than a decreased
signal in HKc/DR following TGF-β1 treatment (Fig. 2B, HKc/DR).
Furthermore, it was visually evident that the number of genes
whose expression changed by more than 2-fold in TGF-β1-treated
cells was much higher in HKc/HPV16 than in HKc/DR (Fig. 2B).
Pairwise comparisons identiﬁed 1160 differentially expressed
genes (DEG) that had changed by at least two-fold after treatment
with TGF-β in HKc/HPV16: 549 genes were up-regulated and 611
genes were down-regulated. In contrast, only 150 DEG (about
8-fold less than found in HKc/HPV16) were identiﬁed following
TGF-β treatment of HKc/DR: 114 genes were up-regulated and
only 36 genes were down-regulated (Fig. 2C). We generated Venn
diagrams by combining the separate gene lists obtained from the
Genesifter analysis, and then manually identiﬁed the common
genes between the two stages (Fig. 2D). We found 77 genes that
were up-regulated (listed in Table S2), and 11 genes down-
regulated (listed in Table S3) by TGF-β in both HKc/HPV16 and
HKc/DR (Fig. 2D). In addition, 62 genes (37 up-regulated and 25
down-regulated) were regulated by TGF-β1 in HKc/DR but not in
HKc/HPV16 (Table S4).
Validation of TGF-β induced genes by real-time PCR
To validate the array data, we performed quantitative RT-PCR
for ﬁve genes (ITGB6, INHBA, VIM, COL4A1, and FN1) whose
expression was increased by TGF-β in both HKc/HPV16 and HKc/
DR. We conﬁrmed by RT-PCR that TGF-β up-regulated the expres-
sion of these ﬁve genes in comparison with untreated controls in
both HKc/HPV16 (Fig. 3A) and HKc/DR (Fig. 3B). A comparison of
the fold induction of each of these ﬁve genes as determined by
microarray and RT-PCR found that induction of gene expression as
determined by microarrays was consistently several fold less than
that determined by RT-PCR (Fig. 3).
Pathways and biological processes affected by TGF-β in HKc/HPV16
and HKc/DR
To explore which pathways were affected by TGF-β1 treatment,
we categorized the signiﬁcant DEG using the KEGG pathway
analysis tool within the GeneSifter software. Pathways with
z-scores 42 oro2 in either HKc/HPV16 or HKc/DR were
compared. In HKc/HPV16, pathways altered by TGF-β1 included
the cell cycle and mitogen-activated protein kinase (MAPK)
Fig. 1. TGF-β activation of a Smad-responsive luciferase reporter construct in HKc/
HPV16 and HKc/DR. Four HKc/HPV16 and their corresponding HKc/DR lines (d-1,
d-2, d-4 and d-5) were transiently transfected in triplicate wells per experimental
condition with the p6SBE-Luc reporter construct and pRL-SV40. Cells were treated
without or with the indicated concentrations of TGF-β1 24 h after transfection, and
harvested for dual luciferase assay after 22 h of TGF-β treatment. Fireﬂy luciferase
values, measured in Relative Light Units (RLU), were normalized against Renilla
luciferase values, and the results expressed as fold induction over control (without
TGF-β).
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Fig. 2. Experimental design and initial analysis of microarray experiments. (A) Experimental design: Four separate HKc/HPV16 lines and their respective HKc/DR
counterparts were treated without or with 40 pM TGF-β for 48 h before harvesting. Labeled RNA samples, using a dye-swap design, were hybridized to Agilent 444k whole
human genome microarrays for each of the HKc/HPV16 and HKc/DR lines, resulting in eight microarrays per transformation stage of the model system. RNA ampliﬁcation,
hybridization, washing and scanning for each individual donor (HKc/HPV16 and HKc/DR) were performed at the same time on separate dates. (B) Scatter plot of gene
expression levels detected by microarray analysis described in A. Red: genes up-regulated byZ2-fold; green: genes down-regulated byZ2-fold; gray: genes exhibiting no
statistically signiﬁcant change, oro2-fold change in expression between TGF-β treated and control cells. (C) Numbers of genes signiﬁcantly changed in HKc/HPV16 and HKc/
DR as a consequence of TGF-β treatment. (D) Venn diagrams showing how many genes are up- or down-regulated (Z 2 fold) in all four HKc/HPV16 and HKc/DR lines after
TGF-β treatment, and how many of the TGF-β regulated genes are common between HKc/HPV16 and HKc/DR. Red:Z2-fold up-regulated, greenZ2-fold down-regulated.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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pathways, with many cell cycle genes being down-regulated, as
expected, by TGF-β1 (Fig. 4A, HKc/HPV16). However, the same
pathways were virtually non-responsive to TGF-β1 treatment in
HKc/DR (Fig. 4A, HKc/DR). This was not surprising since previous
studies from our laboratory demonstrated that HKc/HPV16 are as
sensitive to the growth inhibitory effects of TGF-β as normal HKc,
while HKc/DR are completely resistant (Creek et al., 1995; Mi et al.,
2000). Tables S5 and S6 present a list of the cell-cycle and MAPK
genes that were signiﬁcantly up- or down-regulated in response to
TGF-β1 in HKc/HPV16, but not in HKc/DR.
Interestingly, pathways related to EMT (focal adhesion/ECM-
receptor interaction and cell communication pathways) were
induced by TGF-β to a similar extent in both HKc/HPV16 and
HKc/DR, based upon the number of signiﬁcantly changed genes
(Fig. 4A, compare HKc/HPV16 with HKc/DR). Table S7 shows a list
of the genes changed in these pathways that were up- or down-
regulated by TGF-β1 in HKc/HPV16 and HKc/DR.
GO analysis conﬁrmed and expanded upon the results of the
KEGG pathway analysis: genes down-regulated by TGF-β1 in HKc/
HPV16 were related to the cell cycle (Fig. 4B) and many genes
belonging to processes such as cell adhesion, cell-matrix adhesion
or migration and other related processes were up-regulated in
HKc/HPV16 (Fig. 4B). In HKc/DR, genes belonging to cell cycle-
related processes were not responsive to TGF-β treatment, while a
majority of the genes belonging to the cell-adhesion, cell-matrix
adhesion or migration, and other related processes were up-
regulated to a similar extent in HKc/DR, compared to HKc/HPV16
(Fig. 4C). Many of the speciﬁc gene targets in the TGFβ induced
pathways (Fig. 4A–C, Table S7) such as FN1, VIM, COL4A1, and
ITGB6 participate in cell–cell/cell-matrix adhesion and migration
processes involved in EMT. Therefore, the microarray data suggest
that TGF-β1 inhibits cell proliferation and promotes EMT in HKc/
HPV16, but promotes only EMT in HKc/DR.
Decreased protein levels of E-cadherin and increased protein levels
of ﬁbronectin in both HKc/HPV16 and HKc/DR treated with TGF-β
To functionally validate the role of TGF-β as an inducer of EMT
at both early and late stages of HPV-mediated transformation
in our in vitro model, we studied events associated with EMT in
HKc/HPV16 and HKc/DR treated without and with TGF-β1. At the
protein level, E-cadherin, an epithelial cell marker, was signiﬁ-
cantly reduced in HKc/HPV16 and HKc/DR following TGF-β1
treatment (40 pM for 48 h) (Fig. 5A). In addition, the mesenchymal
marker ﬁbronectin (FN1) was induced by TGF-β1 in a time-
dependent manner in HKc/HPV16 and HKc/DR (Fig. 5B). Interest-
ingly, the basal cellular levels of ﬁbronectin were much lower in
HKc/DR than in HKc/HPV16, so that following 96 h of TGF-β1
treatment, ﬁbronectin levels in HKc/DR are about the same as in
HKc/HPV16 in the absence of TGF-β (Fig. 5B). These changes in
ﬁbronectin expression determined by Western blot analysis were
also conﬁrmed by immunoﬂuorescence confocal analysis of HKc/
HPV16 and HKc/DR treated without or with 40 pM TGF-β1 for 96 h
(Fig. 5C). These ﬁndings show that TGF-β1 treatment of both
HKc/HPV16 and HKc/DR induces markers of EMT.
Effect of TGF-β on cell morphology in HKc/HPV16 and HKc/DR
We next compared the morphological changes induced by
treatment of HKc/HPV16 and HKc/DR with TGF-β1. We cultured
HKc/HPV16 and HKc/DR in the absence and presence of TGF-β1
(40 pM) for 4 days and examined the cells under phase contrast
light microscopy (Fig. 6A). After TGF-β treatment, HKc/HPV16
exhibited a signiﬁcant increase in cell size compared to the
control. Furthermore, HKc/HPV16 also showed the presence of
“rufﬂes” along the cell membrane (Fig. 6A, top panel). In contrast,
treatment of HKc/DR with TGF-β did not result in any marked
changes in cell size. However, more prominent cell surface
protrusions were observed in HKc/DR treated with TGF-β1
(Fig. 6A, lower panel) compared to their respective controls and
to TGF-β1 treated HKc/HPV16.
TGF-β causes the actin cytoskeleton to reorganize in HKc/HPV16
and HKc/DR
During EMT, the actin cytoskeleton is re-arranged. Therefore,
we sought to determine whether TGF-β causes re-arrangements of
the actin cytoskeleton in HKc/HPV16 and HKc/DR. We stained the
cells for F-actin using Alexa ﬂuor 488-phalloidin, and examined
the effect of TGF-β1 on the actin cytoskeleton by confocal micro-
scopy. In the absence of TGF-β1, HKc/HPV16 showed an orderly
organization of cortical F-actin ﬁlaments (Fig. 6B). Treatment of
HKc/HPV16 with TGF-β resulted in ﬁlopodia-like protrusions seen
as slender “brushlike” projections on the cell surface (Fig. 6B).
Some cortical actin ﬁlaments were also detected in TGF-β-treated
HKc/HPV16, although to a lesser extent than in controls. HKc/DR
were characterized by a radial network of F-actin ﬁlaments at the
plasma membrane, in the absence of TGF-β. Upon treatment with
TGF-β1, HKc/DR displayed intense cortical actin staining, as well as
a marked increase in the number and density of lamellipodia or
actin-rich microspikes (Fig. 6B), indicative of EMT. The results
show that TGF-β modulates cell morphology and reorganizes the
actin cytoskeleton in both HKc/HPV16 and HKc/DR.
Fig. 3. RT/PCR validation of microarray results. Fold-change induced by TGF-β of
the expression of a panel of genes, determined by microarray analysis (open bars)
and RT-PCR (solid bars) in HKc/HPV16 (A) and HKc/DR (B).
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Fig. 4. KEGG pathway analysis of differentially expressed genes. (A) Summary of KEGG analysis results for genes belonging to the cell cycle, MAPK, focal adhesion/ECM-
receptor interaction and cell communication pathways found changed by TGF-β treatment in HKc/HPV16 (upper panel) and HKc/DR (lower panel). Red:Z2-fold up-
regulated; greenZ2-fold down-regulated by TGF-β. (B, C) Gene ontology analysis of differentially expressed genes as determined using the GeneSifter software. The y-axis
represents the percentage of genes changed up or down, within each group of genes (in each cellular process) that changed in response to 48 h of TGF-β treatment (40 pM) in
HKc/HPV16 (B) and HKc/DR (C) byZ2-fold. Data are grouped into different ontology groups (x-axis) and each is further separated into increased (red bars) and decreased
(green bars) expression. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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TGF-β increases cell migration in both HKc/HPV16 and HKc/DR
An important property of cells undergoing EMT is their ability to
migrate. To determine whether TGF-β increased cell migration in
HKc/HPV16 and HKc/DR, we performed an in vitro scratch assay.
Conﬂuent HKc/HPV16 and HKc/DR were treated with or without 40
pM TGF-β for 12 h, then cell monolayers were scratched to produce
wounds, and images were captured under phase contrast microscopy
immediately after the scratch (time 0) and at 6 h intervals until the
wound closed. The gap width was measured by ImageJ on images
collected at each time point, starting at 6 h after the scratch and at
6 h intervals thereafter, up to 36 h of observation. TGF-β treatment
led to increased migratory behavior and wound closure in both HKc/
HPV16 and HKc/DR compared to their respective controls (Fig. 6C).
The scratch closed with approximately the same dynamics in HKc/
HPV16 and HKc/DR treated with TGF-β, however, HKc/DR closed the
gap somewhat faster than HKc/HPV16 and more completely (Fig. 6C).
Untreated cells also behaved in comparable ways, failing to close the
gap during the time of observation (Fig. 6C).
Discussion
Relative roles of E7 and TGF-β in the control of proliferation
of HPV16-transformed cells
A major advantage of our model for HPV16-mediated transfor-
mation of human cells is that it allows for studies of the interplay
of HPV16 oncoproteins with cellular pathways key to growth
Fig. 5. TGF-β decreases E-cadherin and increases ﬁbronectin protein levels in HKc/HPV16 and HKc/DR. Whole-protein lysates were prepared from HKc/HPV16 and HKc/DR
treated without or with TGF-β (40 pM) for 48 h (A) or for the indicated times (B) and Western blot analysis was performed for E-cadherin (A), ﬁbronectin (B) or tubulin (A, B)
as a loading control. (C) Control and TGF-β treated (40 pM for 96 h) HKc/HPV16 and HKc/DR were ﬁxed in 4% paraformaldehyde. Slides were stained with DAPI to visualize
nuclei (blue; panels a, d, g, and j) and with anti-ﬁbronectin antibody (FN1) (red; panels b, e, h, and k). Merged images are presented in panels c, f, i, and l. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
S. Kowli et al. / Virology 447 (2013) 63–7368
Fig. 6. TGF-β induces morphological changes, re-organizes actin cytoskeleton, and enhances cell migration in HKc/HPV16 and HKc/DR. (A) Cells were treated with or without
TGF-β (40 pM for 4 days) and examined under phase contrast using a Zeiss Axiovert 200 inverted microscope. White arrows show projections protruding out from the cell
surface of HKc/HPV16 and HKc/DR. (B) F-actin was stained with Alexa ﬂuor-488 labeled Phalloidin and nuclei with DAPI in HKc/HPV16 and HKc/DR, which were then
visualized under a confocal microscope. F-actin, green: panels a, d, g and j; nuclei, blue: panels b, e, h and k. Merged images are presented in panels c, f, i, and l.
(C) Quantiﬁcation of scratch assay. HKc/HPV16 and HKc/DR were grown to conﬂuence and treated with or without 40 pM TGF-β1 for 12 h. Wounds were then incised by
scratching the cell monolayer with a pipet tip, and incubation with or without TGF-β1 continued for 36 h. Images were captured under phase-contrast microscopy at 6 h
intervals after the incision and quantiﬁed with ImageJ. At least ten measurements of the width of the gap were assessed for each time point, starting at the 6 h time point and
continuing until 36 h after the scratch. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article).
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control, transformation, and progression. The results we present
here, combined with those we published over the years about the
role of TGF-β in this model (Creek et al., 1995; Mi et al., 2000;
Baldwin et al., 2004; Hypes et al., 2009; Chen et al., 2013) allow us
to begin describing how the interplay of HPV oncoproteins and
TGF-β drives in vitro progression of HPV16-transformed cells. In
normal HKc, TGF-β causes marked (but reversible) growth inhibi-
tion (Shipley et al., 1986; Batova et al., 1992) and promotes EMT
(Fukawa et al., 2012). In HPV16-immortalized cells, E7-mediated
degradation of RB (Munger et al., 1989) and E7 interference with
p300 (Bernat et al., 2003; Fera and Marmorstein, 2012; Pouponnot
et al., 1998) and with the Smads (Habig et al., 2006; Lee et al.,
2002) may be expected to produce resistance to growth inhibition
by TGF-β from the very beginning of the transformation process.
However, we have shown that early passage HKc/HPV16 are just as
sensitive to growth inhibition by TGF-β as normal HKc (Creek
et al., 1995; Mi et al., 2000) but progressively become resistant to
growth inhibition by TGF-β during in vitro progression. The
explanation for this apparent paradox may reside in the observa-
tion that TGF-β inhibits E6/E7 expression by a mechanism that
involves decreased binding of NF1/Ski complexes with the HPV16
upstream regulatory region (URR) (Baldwin et al., 2004). This
decrease is due primarily to a dramatic loss of Ski protein
produced by TGF-β treatment of HKc, including HKc/HPV16 and
HKc/DR (Chen et al., 2013). Ski complexes with NF1 and increases
its transcriptional activity on the HPV16 URR, therefore a loss of
Ski translates into decreased E6/E7 transcription (Baldwin et al.,
2004). Our data thus far support the interpretation that the
activities of HPV16 E7 and TGF-β exist in a balance: E7 interferes
with TGF-β inhibition of growth; TGF-β, in turn, decreases E7
expression. Therefore, TGF-β treatment of HKc/HPV16 not only
increases the expression of CDK inhibitors, but also inhibits E6/E7
expression, lessening the impact of the HPV oncoproteins on Rb
and p53. We postulate that this balance of activities in HKc/HPV16
leads to growth inhibition by TGF-β that is comparable in
magnitude to that of normal HKc, although elicited through
somewhat different mechanisms.
As HKc/HPV16 progress toward the HKc/DR phenotype, E6/E7
levels rise (our unpublished observation). We postulate that this
increase in E6/E7 expression may be due to the fact that Ski is much
more abundant in HKc/DR than in HKc/HPV16 (Baldwin et al., 2004;
Chen et al., 2013) and consequently NF1/Ski-mediated activation of
the URR may be more robust. Even though TGF-β still causes Ski
degradation in HKc/DR, the levels of Ski in TGF-β treated HKc/DR are
comparable to those of untreated normal HKc (Chen et al., 2013).
Accordingly, TGF-β dramatically suppresses E7 expression in HKc/
HPV16, but not that much in HKc/DR (Borger et al., 2000). During
progression to HKc/DR, as E6 levels rise, p53 protein levels decline.
We and others have shown that a loss of p53 causes YY1 protein
levels to increase (Sui et al., 2004; Bheda et al., 2008). This leads to a
global shift in cell responses co-regulated by YY1, which has been
shown to interfere with TGF-β and BMP signaling, preventing TGF-β
induction of differentiation in HKc (Kurisaki et al., 2003).
During in vitro progression from HKc/HPV16 to HKc/DR, HKc/
HPV16 progressively lose TGFBRI by mechanisms directly depen-
dent upon E6/E7 expression (Hypes et al., 2009; Mi et al., 2000).
Consequently, Smad signaling decreases to about 50% of normal
(shown here); Ski levels rise; E6/E7 levels increase; and sensitivity
to growth control by TGF-β decreases until, at the HKc/DR stage,
TGF-β no longer suppresses growth and only partially inhibits
HPV16 E7 expression (Borger et al., 2000; Creek et al., 1995). Ski's
role in this process is relatively clear. Whether and how YY1
participates in these processes, and what other factors are involved
remain to be investigated.
During progression of HKc/HPV16 to HKc/DR we observed a
marked decrease in the basal, steady-state levels of ﬁbronectin
protein, although TGF-β stimulated ﬁbronectin expression at both
stages of in vitro progression. Although initially puzzling, this
observation can be probably viewed in the same context as those
discussed above, as a reversible change depending on the chan-
ging levels of E6/E7 and their interactions with cellular proteins. It
has been reported that the HPV oncoproteins induce EMT markers
(Hellner et al., 2009) therefore a robust expression of ﬁbronectin in
HKc/HPV16 is not surprising. In HKc/DR, which express E7 at
higher levels, ﬁbronectin expression in the absence of TGF-β is
very low. This apparently contradictory behavior ﬁnds support in
the literature, as it has been reported that transient expression of
E7 results in inhibition of ﬁbronectin transcription, and that
ﬁbronectin promoter activity is lower in HPV-positive cell lines
than in HPV-negative ones (Rey et al., 2000). We postulate that the
apparent contradiction between these two published reports may
result from different levels of E7 being expressed in the different
models utilized in these two studies. While this conclusion
remains to be conﬁrmed in a single experimental system, the
observations summarized here above bring forth the idea that
changing levels of E7 (and E6, as well) during progression of HPV-
transformed cells lead to different gene/protein expression land-
scapes that, in turn, profoundly affect cell behavior.
Importantly, all of these interactions are based upon the balance
of activities of cellular factors with HPV oncoproteins, and therefore
are generally reversible, as opposed to a permanent loss of tumor
suppressor gene activity due to gene deletion or mutation (as for
example with p53 in most solid tumors) or increased oncogene
activity due to mutation, gene ampliﬁcation or insertional activation.
Differential effects of TGF-β on cyclins in HKc/HPV16
and HKc/DR
As expected, gene expression analysis shows that TGF-β down-
regulates the expression of cyclins A1, A2, B1 and B2 and up-
regulates the expression of cyclin-dependent kinase inhibitors p21,
p57 and p15 in HKc/HPV16, but not in HKc/DR (Table S5). In
normal epithelial cells, TGF-β mediates G1-arrest by the Smad-
dependent induction of cyclin-dependent kinase inhibitors p21
and p15 (reviewed in Massague and Gomis, 2006). Previous
studies have demonstrated that TGF-β decreases the expression
of c-myc in normal murine mammary gland epithelial cells as well
as NIH3T3 cells, also by Smad-dependent mechanisms (Hsu et al.,
1994). Consistent with our growth data, our microarray results
show inhibition of myc expression by TGF-β in HKc/HPV16, but not
in HKc/DR. In HKc/HPV16, TGF-β also suppressed the expression of
cdc2, a well-established cell cycle regulator important for cell
division, by approximately 5-fold. Binding of cdc2 to cyclin B1 is
required for its activity. Cyclin B1 was also down-regulated by 5-
fold by TGF-β in HKc/HPV16 (Table S5). Up-regulation of cell cycle
control genes such as CDKN1A (p21), CDKN2B (p15) and down-
regulation of myc by TGF-β are known to be mediated via Smad
activation (reviewed in Massague and Gomis, 2006).
Stimulation of growth and EMT by TGF-β in tumor cells
Originally reported as a tumor suppressor, TGF-β can also stimu-
late growth of tumor cells depending on the cell type. During
progression tumor cells break through the basement membrane,
migrate and establish themselves at new sites where they lay down
an extracellular matrix (ECM) (Dawes et al., 2007; Garamszegi et al.,
2009). TGF-β can rearrange the cytoskeleton and stimulate cell
migration and invasion in vitro and in vivo in human breast cancer,
colon cancer and pancreatic cancer (Garamszegi et al., 2009; Kalluri
and Neilson, 2003; Kang and Massague, 2004; Lee et al., 2008; Thiery,
2003; Wu and Zhou, 2008; Yang and Weinberg, 2008). Matrix
metalloproteases (MMPs) play a role in degrading the basement
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membrane (Kalluri and Neilson, 2003; Thiery, 2003). The expression
of MMP9 was found to be upregulated by TGF-β at both the HKc/
HPV16 and HKc/DR stages, implicating TGF-β in the processes of
tumor progression in our model. Data from several microarray studies
have demonstrated induction of genes involved in ECM by TGF-β
(Dawes et al., 2007; Kalluri and Neilson, 2003). We show here that
treatment of HKc/HPV16 and HKc/DR with TGF-β up-regulated the
expression of genes involved in ECM and cell adhesion processes
including: collagens (COL4A1), integrins (ITGAV, ITBG6), and laminins
(LAMA3, LAMC2). Integrins serve as cell surface receptors for ECM
components, by which the cells attach to and migrate across the ECM
(Dawes et al., 2007). In addition, the expression of vimentin (inter-
mediate ﬁlament), N-cadherin (mesenchymal marker) and ﬁbronec-
tin (ECM component and mesenchymal marker) was also induced in
both HKc/HPV16 and HKc/DR (Table S2). Increased expression of TGF-
β1 has been observed in ﬁbrotic diseases as well as human cancers
(Hsu et al., 1994; Khalil et al., 2001; Oft et al., 1998) and endogenous
TGF-β1 production after exogenous stimulation by TGF-β1 has been
noted to support EMT (Yao et al., 2004). Our microarray results also
demonstrate increased levels of TGF-β1 mRNA following TGF-β1
treatment of HKc/HPV16 and HKc/DR (Table S2) suggesting a self-
induction of TGF-β expression. It is possible that for the maintenance
of EMT, HPV16 transformed cells may require continuous TGF-β
production which is stimulated in an autocrine or paracrine manner.
TGF-β modulation of E-cadherin expression
Epithelial cells are sealed to one another by adherent junctions, as
well as tight junctions (Thiery, 2003; Yang and Weinberg, 2008). E-
cadherin is a hallmark epithelial marker, which forms tight cell–cell
associations with E-cadherin of neighboring epithelial cells, thus
preventing the dissociation and movement of epithelial cells from
their origin. An early event in EMT is the disruption of epithelial
junctions. An increasing body of literature documents that E-
cadherin repression in several carcinomas correlates well with tumor
progression (Ewing et al., 1995; Kasai et al., 2005). In vitro studies
show that treatment of human epithelial cells of various origins with
TGF-β results in the down-regulation of E-cadherin expression
(Bhowmick et al., 2001; Kasai et al., 2005; Miettinen et al., 1994).
Consistent with previous reports (Bhowmick et al., 2001; Kasai et al.,
2005; Miettinen et al., 1994), we show that 48 h treatment with TGF-
β induces loss of E-cadherin protein in both HKc/HPV16 to HKc/DR.
However, our microarray data did not reveal any of the known E-
cadherin repressors such as Snail, Slug, and Twist (Wu and Zhou,
2008) as signiﬁcantly changed (below 2-fold cut-off) at the mRNA
level, following TGF-β treatment of HKc/HPV16 and HKc/DR. There-
fore, the mechanism by which TGF-βmediates down-regulation of E-
cadherin in our model remains to be determined. It has been shown
that TGF-β can disrupt the stability of E-cadherin junctions via Rho-
dependent mechanisms (Bruewer et al., 2004). Furthermore, studies
using siRNA against Smad2 have shown that Smad2 inhibition
suppresses TGF-β-mediated EMT (Kasai et al., 2005). Concomitant
with the loss of E-cadherin expression, HKc/HPV16 and HKc/DR
expressed increased levels of the mesenchymal marker ﬁbronectin
after treatment with TGF-β. It has also been demonstrated that
overexpressing Smad3 increases ﬁbronectin expression (Uemura
et al., 2005). These results are in accordance with several published
reports on the effects of TGF-β during EMT (Frolik et al., 1984; Hsu
et al., 1994; Thiery, 2003; Zavadil and Bottinger, 2005).
TGF-β-mediated reorganization of the cytoskeleton
Beyond changes in phenotypic markers, we found that TGF-β
treatment of HKc/HPV16 and HKc/DR resulted in the reorganization
of the actin cytoskeleton from cortical actin to actin microspikes,
and induced cell migration, which is dependent on the dynamics of
the actin cytoskeleton. In line with its ability to destabilize adherens
junctions, TGF-β mediates actin re-organization via the Rho-
GTPases (Edlund et al., 2002; Vardouli et al., 2008). Therefore it is
possible that TGF-β-induced cell migration in HKc/HPV16 and HKc/
DR may be the result of TGF-β mediated Rho-dependent mechan-
isms that reduce E-cadherin expression and re-organize the actin
cytoskeleton.
Conclusions
This study integrates microarray results with morphological
and biochemical observations to show that TGF-β switches from a
growth suppressor and inducer of EMT to solely a stimulator of
EMT during in vitro progression of HPV16-transformed HKc. This
switch occurs in the presence of considerable residual SMAD
signaling which; however, is no longer sufﬁcient to cause growth
inhibition, known to occur through canonical TGF-β signaling
pathways. Of particular importance is the ﬁnding that TGF-β not
only inhibits cell proliferation, but also induces several features of
EMT at early stages of HPV16-mediated transformation. Hence, the
gene expression patterns demonstrated by our microarray analysis
suggest that branches of the same signaling pathways are cut-off,
rather than entirely different pathways being activated by TGF-β
in HKc/DR. TGF-β signaling may branch within the Smad depen-
dent route, because many of the gene expression changes identi-
ﬁed in HKc/DR are known to be Smad-mediated, at least in other
systems (Massague and Gomis, 2006). Alternatively, non-canonical
signaling pathways may take over at the HKc/DR stage, with the
residual Smad signaling playing at best an accessory role in the
process of EMT induction. While the overall patterns of gene
expression we observed in response to TGF-β recapitulate
mechanisms of TGF-β action that have been identiﬁed in other
systems, here the interactions of TGF-β signaling pathways with
responses elicited by E6 and E7 provide unique circumstances that
dictate functional effects speciﬁc to HPV-mediated cancers. In this
context, it will be important to dissect at which branch point/s in
the TGF-β signaling cascade, TGF-β activities bifurcate to exert
antiproliferative and proEMT actions in HPV-transformed cells.
Materials and methods
Cell culture and TGF-β1 treatment
The four HKc/HPV16 lines and their corresponding HKc/DR
lines used in this study, and the methods for their establishment
and culture have been previously described (Pirisi et al., 1988,
1987).
For microarray studies, cells were cultured to 70% conﬂuence
and then fed fresh medium without or with 40 pM TGF-β1 (R&D
Systems, Inc.) at time 0 and then again at 24 h. Cells were
harvested for RNA extraction after 48 h of TGF-β1 treatment. By
this time, cells were 90% conﬂuent.
TGF-β induction of a Smad-responsive reporter construct
A ﬁreﬂy luciferase reporter construct containing six tandem
Smad-binding elements (SBE) cloned upstream of the SV40
promoter (p6SBE-Luc) and a control plasmid, identical to p6SBE-
Luc in overall structure, but carrying six mutated inactive SBE
(p6SME-Luc; both a gift of Dr. Scott Kern) (Dai et al., 1998) were
co-transfected with the Renilla luciferase expression vector pLR-
SV40 (Promega) into HKc/HPV16 and HKc/DR in six-well plates.
Cells were treated with TGF-β1 or an equivalent amount of 4 mM
HCl–1 mg/mL BSA vehicle (control) at the indicated doses 24 h
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after plating, and harvested for Dual Luciferase Assay (Promega)
after 22 h of TGF-β1 treatment. Fireﬂy luciferase values were
normalized for Renilla luciferase and expressed as relative light
units (RLU). Results were expressed as fold-change of RLU values
of TGF-β treated cells over untreated controls.
Microarray and data analysis
RNA samples were obtained from HKc/HPV16d-1, d-2, d-4, and
d-5 and their corresponding HKc/DR lines (Pirisi et al., 1988).
Comparisons between control and TGF-β treated groups for each
HKc/HPV16 and HKc/DR line were replicated using a dye-swap
design, thereby giving 16 sets of hybridizations for both the HKc/
HPV16 stage and the HKc/DR stage of the in vitro model system.
Total RNA was extracted from control and TGF-β1 treated cells
using the Total RNA Isolation Mini Kit (Agilent Technologies, Santa
Clara, CA). RNA quality and quantity were assessed on an Agilent
2100 Bioanalyzer. Only RNA samples with RNA Integrity Number
(RIN) 9.8 or above were used. Total RNA (500 ng per sample) was
ampliﬁed and labeled using the Agilent Low RNA Input Linear
Ampliﬁcation Kit. RNA Spike-Ins (Invitrogen) was used as an
internal control. Hybridization was performed on Whole Human
Genome 444k 60mer oligonucleotide microarrays (Agilent Tech-
nologies, Santa Clara, CA). Images were quantiﬁed and normalized
using ImaGene v7.5 software (BioDiscovery, Hawthorne, CA). Data
were analyzed using GeneSifter software (Geospiza, Seattle, WA)
and subjected to KEGG Pathway and Gene Ontology (GO) Analysis.
The pathway and ontology analysis are based on a z-score report
that identiﬁes signiﬁcantly changed gene-lists based on the total
number of genes on the array. A z-score greater than 2 or less than
2 is considered signiﬁcant.
Quantitative real time PCR
To validate microarray results, real-time RT-PCR was performed
for 5 genes (FN1, VIM, ITGB6, INHBA and COL4A1). Reverse
transcription was performed with 1 μg total RNA using the
iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA) following
the manufacturer's protocol. Serial dilutions of a cDNA sample
were used to estimate primer efﬁciency for each gene. RT-PCR was
carried out using gene-speciﬁc primers with the iQ-SYBR green kit
(Bio-Rad) using the same total RNA used in the microarray study,
but without performing whole-RNA ampliﬁcation. Samples were
assayed either in duplicate or triplicate. The Pfaffel quantiﬁcation
method (Pfafﬂ, 2001) was implemented to normalize all values
against those for the reference gene beta-D-glucuronidase (GUSB)
to determine the difference in the expression of the gene of
interest. The primers were chosen using Primer3 software and
their speciﬁcity for the selected genes was veriﬁed by performing
a Blast analysis. The sequences of the primers used are listed in
Supplementary Table 1.
Phase contrast microscopy
HKc/HPV16 and HKc/DR were grown in 100-mm tissue culture
dishes. Cells were treated for 4 days with or without 40 pM TGF-
β1 with fresh TGF-β1 administered every 24 h in fresh medium.
After 4 days, control and TGF-β1 treated HKc/HPV16 and HKc/DR
were examined for changes in morphology under phase contrast
using a Zeiss Axiovert 200 inverted microscope (Carl Zeiss,
Munich, Germany).
Western blot analysis immunoﬂuorescence
Cell lysates (15 μg protein) were resolved on an 8% SDS-PAGE
gel, transferred to PVDF membranes (BioRad) and probed with
anti-E-cadherin (Santa Cruz BioTech, Santa Cruz, CA, sc-71008),
anti-Fibronectin (Sigma, St. Louis, F3648) or anti-Tubulin (Sigma)
antibodies. Proteins were detected using the ECL Western Blotting
detection kit (Amersham Biosciences, GE Health Care Life Science,
Pittsburg, PA).
Immunoﬂuorescence studies
HKc/HPV16 and HKc/DR were grown on coverslips pre-coated
with Poly-L-lysine and collagen type I (Sigma) overnight at 37 1C.
The cells were treated for 4 days without or with 40 pM TGF-β1
with administration of fresh TGF-β1 every 24 h. After 4 days,
coverslips were ﬁxed with 4% paraformaldehyde (PFA), probed
with primary anti-ﬁbronectin antibody (Sigma, F3648) at 1:100
dilution in 2% blocking solution, followed by incubation with Alexa
ﬂuor-546 labeled secondary antibody (Invitrogen, Life Technolo-
gies Corporation, Grand Island, NY) at 1:250 dilution in 2%
blocking solution. Cells were also stained with Alexa Fluor 488-
Phalloidin to detect F-actin (Invitrogen, A12379) and nuclei were
stained with DAPI (Invitrogen). Coverslips were mounted using
Vectashield mounting media (VectorLabs, Burlingame, CA). Images
were captured using a LSM Meta 510 Confocal Microscope (Carl
Zeiss) and a Zeiss Axiovert 200 inverted ﬂuorescence microscope.
Cell migration assay
HKc/HPV16 and HKc/DR were grown to conﬂuence and treated
with or without TGF-β1 (40 pM) for 12 h. A wound was then
incised by scratching the cell monolayers using a pipette tip.
Images were captured under phase contrast microscopy immedi-
ately after the incision (time 0) and at 6 h intervals until the
wound closed. At least six different regions on each tissue culture
dish for each condition were examined and imaged. Image analysis
to quantify the assay was conducted using ImageJ (NIH).
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